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or nonimmunologists, a daunting and rapidly
evolving immunologic vocabulary, our incom-
plete understanding of both normal and abnor-
mal immune function, and multiple interrelated
complex immune cellular pathways can be a barrier to
using basic immunology to understand and improve care
for patients with type 1 diabetes. Our task in this review is
to introduce current immune concepts speciﬁcally rele-
vant to type 1 diabetes. Because our understanding is not
complete, as evidenced perhaps by our lack of standard
immunotherapy to prevent type 1 diabetes, we can only
provide a partial framework. Perhaps the simplest frame-
work (which may be wrong) is to consider the develop-
ment of type 1 diabetes as the balance between regulatory
and effector T lymphocytes. We know that in the absence
of a major portion of regulatory T lymphocytes in a rare
syndrome caused by mutation of the FOXP3 gene, most
infants (even neonates) develop type 1 diabetes. Central to
the development of type 1 diabetes are T lymphocytes with
speciﬁc T-cell receptors that recognize islet molecules.
When a T-cell is activated through its receptor, it can
orchestrate protection from infection or autoimmunity,
depending on the target. Other T-cells can suppress or
enhance autoimmunity (either in general or only for T
lymphocytes in islets). The activation of a T-cell involves
multiple different cell types and genes, as we will discuss.
IMMUNE RESPONSE
The modern era of immunology began with the clonal
selection theory independently expressed by David W.
Talmage and Sir Frank Macfarlane Burnet (1,2). The clonal
selection theory postulates that a foreign antigen entering
the body binds to one unique antibody selected from an
unlimited repertoire of antibodies formed early in the
organism’s life. This explains how the immune system is
able to recognize and respond to a virtually inestimable
number of foreign antigens.
The immune system is a complex network of cells and
organs that functions to protect the body against patho-
gens. This network uses multiple specialized cell types
communicating via cellular interactions and humoral fac-
tors such as cytokines. The immune system is composed
of the adaptive and the innate immune system. The
adaptive immune system is an antigen-speciﬁc system that
generates immunological memory and T-cell and antibody
responses speciﬁc to pathogens or infected cells. The
innate immune system is the ﬁrst line of defense against
pathogens, working to recognize common components
of pathogens so that further immune responses can be
signaled in the presence of foreign pathogens. The
natural mechanisms involved in host defense can turn
against self, promoting the development of an auto-
immune response to antigens of the host’s own tissue.
Importantly, the majority of autoimmune responses
against self-antigens do not result in disease progres-
sion. Only when sustained autoimmune responses cause
tissue damage is the consequence of this destructive
process identiﬁed as autoimmune disease.
ADAPTIVE IMMUNITY AND TYPE 1 DIABETES
The adaptive immune system is an antigen-speciﬁc struc-
ture that discriminates non-self molecules through the
recognition of peptide antigens using receptor interactions
between T-cells and antigen-presenting cells (APCs). This
highly speciﬁc system uses receptor interaction between
T-cells and APCs to discriminate self from nonself. Adap-
tive immunity establishes long-term immunological mem-
ory responses that trigger clonal expansion of T
lymphocytes, which in turn cross-talk to B-cells to pro-
duce antigen-speciﬁc antibodies. The components of adap-
tive immunity are T and B lymphocytes, each with their
own structurally unique cell receptors, which are somati-
cally generated during thymic cell development. The adap-
tive immune system depends on the ability to assemble
rearranged genes for both the T-cell receptor (TCR) and
the immunoglobulin gene. This ability results from two
genes known as RAG-1 and RAG-2 and their gene products
that encode a recombinase involved in somatic recombi-
nation. The adaptive immune system allows T- and B-cells
to generate an enormously diverse response to different
pathogens. Both the naive T- and B-cell receptor repertoire
are generated by interaction with self-ligands, such as the
major histocompatibility complex (MHC), which in turn
can signal to T- and B-cells to mature and survive. T-cells
that are selected on self-ligands and sustained on self-
ligands are termed “autoreactive T-cells.”
T-cells secrete large quantities of cytokines in response
to antigen-speciﬁc activation and, based on their cytokine
secretion proﬁles, are deﬁned as T-helper type 1 (TH1),
TH2, or TH17 (Fig. 1). TH1 cells mature in response to
interleukin (IL)-12 and produce interferon (IFN)-, which
enhances cellular immunity and is important for intracel-
lular defense, autoimmunity, and anti-tumor response. TH2
cells develop in response to IL-4 and produce IL-4, IL-5,
and IL-13, which enhance humoral immunity and are
important for extracellular defense. IL-2 is essential for
transforming growth factor-–mediated induction of
Foxp3
 regulatory T-cells (Tregs) and for the survival of
Foxp3
 Tregs in the periphery (3,4). Interest in Tregs has
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antibody treatment reverses hyperglycemia in newly diag-
nosed NOD mice, and perhaps also in humans, as a result
of the induction of regulatory T-cells (5,6). Tregs can be
expanded in vitro and in vivo and could be harnessed
therapeutically to treat type 1 diabetes or facilitate toler-
ance to an allogeneic graft (7). An exhaustive review of
Tregs in type 1 diabetes is provided in this issue of
Diabetes.
The TH-17 subset of T helper cells was identiﬁed on the
basis of its ability to produce IL-17A, IL-17F, and IL-22.
TH-17 cells were ﬁrst recognized during assessment of the
involvement of IL-23 in autoimmune disease. IL-23 is a
member of the IL-6 family, and the nuclear receptor RORt
acts as a key transcription factor in this lineage-commit-
ment process (8) (Fig. 1). TH-17 cells provide protection in
certain infections but have also been linked to a number of
autoimmune diseases, a function previously assigned to
TH1 cells and IFN-.T H-17 cells seem to mediate pathology
in uveitis, multiple sclerosis, experimental autoimmune
encephalomyelitis (EAE) psoriasis, and rheumatoid arthri-
tis (9), but it is not entirely clear if the TH-17 pathway is
inﬂuenced in type 1 diabetes. A recent study in NOD
mice indicated that IFN- induced by an adjuvant-free
antigen can reverse hyperglycemia, possibly as a result
of suppression of pathogenic IL-17–producing cells (10).
However, additional research is necessary to establish
to what extent TH-17 cells play a role in type 1 diabetes
pathogenesis.
The HLA complex. Type 1 diabetes is a complex hetero-
geneous disease for which there is a small number of
genes with large effects (i.e., HLA) and a large number of
genes with small effects (11). There are probably many
genetic forms of type 1 diabetes, and most forms are
inﬂuenced by genes within the HLA region on chromo-
some 6p21 (IDDM1). Certain combinations of HLA alleles
are found to be associated with each other on the same
chromosome with a frequency greater than expected, and,
consequently, they are not randomly distributed within the
general population. This phenomenon is known as linkage
disequilibrium, and it is quantiﬁed by the difference be-
tween the observed and the expected frequencies of
certain combinations of alleles. It is the combination of
these alleles on single chromosomes (haplotypes) and
combinations of both chromosomes (one from each par-
ent: genotype) that predominantly determines diabetes
risk.
The principal genes localized within the MHC code for
human leukocyte antigens, or HLA, two molecular classes
of cell surface glycoproteins differing in structure, func-
tion, and tissue distribution. The genes that encode class I
MHC consist of HLA-A, -B, and -C, whereas class II
molecules are encoded by the DR, DQ, and DP genes.
APCs are cell populations specialized to take up patho-
gens and other antigens, present them to lymphocytes, and
provide signals that stimulate the proliferation and differ-
entiation of lymphocytes, generally T lymphocytes (Fig. 2).
The main type of APC that gives rise to T-cell responses is
the dendritic cell. Other cells functioning as APCs include
macrophages, B-cells (12), and, recently, stellate cells (Ito
cells), which appear to be new actors in antigen presen-
tation (13). T-cell activation requires a sustained interac-
tion between a naïve T-cell’s TCR and the MCH-peptide
complex on an antigen presenting (signal 1, signal 2, signal
3; Fig. 2).
Susceptibility to type 1 diabetes is conferred by speciﬁc
HLA DR/DQ alleles (e.g., DRB1*03-DQB1*0201 [DR3] or
DRB1*04-DQB1*0302 [DR4]) (14,15). Each allele is simply
given a number that represents a unique amino acid
sequence. Each sequence binds only certain peptides and
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FIG. 1. CD4
 T-cells have been subdivided into different subsets on the basis of their cytokine production and their functions. TH1, TH2, and Tregs
have been well characterized with respect to factors inﬂuencing their development. Recently, another subset of T-cells has been identiﬁed,
namely TH17, which is distinct from TH1o rT H2 and is characterized by its production of IL-17. TH17 cells may play a crucial role in the induction
of autoimmune tissue injury. In contrast, CD4
CD25
Foxp3
 regulatory T-cells inhibit autoimmunity and protect against tissue injury.
IL-17–expressing T-cells are largely found in the tumor environment, particularly in advanced tumors, but not in the tumor-draining lymph nodes.
Both IL-6 and transforming growth factor (TGF)- induce the differentiation of pathogenic TH17 cells from naive T-cells (3). TH17 cells may play
a role in a range of inﬂammatory conditions including uveitis, multiple sclerosis, experimental autoimmune encephalomyelitis, psoriasis, and
rheumatoid arthritis (9), but there is not yet conclusive evidence that TH17 cells are somehow involved in the pathogenesis of type 1 diabetes
(T1DM).
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genotype associated with the highest risk for type 1
diabetes is the DR3/4-DQ8 (DQ8 is DQA1*0301,
DQB1*0302) heterozygous genotype. In addition, HLA
alleles such as DQB1*0602 are associated with dominant
protection from type 1 diabetes in multiple populations
(16). There is a different disease risk for each MHC
genotype, and although it is possible that only a single
peptide epitope will relate to disease with multiple MHC
genotypes, this remains to be experimentally evaluated.
Aly et al. (17) provided evidence that risk for islet
autoimmunity drastically increased in DR3/4-DQ2/DQ8 sib-
lings who shared both HLA haplotypes identical by de-
scent with their diabetic proband sibling (63% by age 7
years, and 85% by age 15 years) compared with siblings
who did not share both HLA haplotypes with their diabetic
proband sibling. These data suggest that HLA genotyping
at birth may identify individuals at very high risk of
developing type 1 diabetes before the occurrence of clear
signs of islet autoimmunity and, eventually, overt disease.
Class I MHC molecules are expressed in virtually all
nucleated cells, whereas class II molecule expression is
restricted to B lymphocytes, dendritic cells, macrophages,
and activated T lymphocytes. Peptides presented via MHC
class I structures interact with CD8
 T-cells, while those
peptides presented via MHC class II structures interact
with CD4
 T-cells. Once a processed peptide is recognized
through an MHC-TCR interaction, a cascade of signaling
events occurs dependent upon the class of MHC structure
recognized and the T-cell type that is activated. Once
activated, CD4
 T-cells promote T-cell activation and
differentiation, along with the ability to signal B-cells to
generate an antibody response. CD8
 T-cells, when acti-
vated, produce inﬂammatory mediators and can directly
target the destruction of speciﬁc peptide-presenting cells.
Speciﬁc HLA class I alleles also inﬂuence diabetes risk,
after correcting for linkage disequilibrium with DR and DQ
alleles (18,19).
Similar to other autoimmune disorders, in type 1 diabe-
tes, CD4
 and CD8
 T-cells contribute to immune-medi-
ated -cell destruction. Accumulating evidence indicates
that multiple islet antigens, including insulin, are targeted
by MHC class II–restricted autoreactive T-cells (20,21). In
particular, a high degree of T-cell clonal expansion was
observed in pancreatic lymph nodes from two long-term
diabetic patients but not from control subjects. The oligo-
clonally expanded T-cells from diabetic subjects with DR4,
which is a notorious susceptibility allele for type 1 diabe-
tes, recognized the insulin A 1–15 epitope restricted by
DR4. These experiments indicated that clonally expanded,
autoreactive T-cells could be cloned out directly from the
pancreatic draining lymph nodes of NOD mice. Although
intriguing, there are a number of caveats to be considered
in the interpretation of the abovementioned data. The two
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FIG. 2. Exogenous antigens are taken into the APCs, cleaved into peptides, and coupled with MHC molecules for presentation and recognition
by naïve T-cells. T-cells bear on their surface unique receptors created by genetic recombinatorial processes. Signal 1 is delivered through the
TCR when it engages an appropriate peptide-MHC complex. To facilitate this interaction, adhesion structures on both the APC and T-cell interact;
for example, intracellular adhesion molecule-1 (ICAM-1) on the APC interacts with leukocyte function–associated antigen-1 (LFA-1) on the
T-cell. Another adhesion receptor pair is formed between CD58 (LFA-3) on the APC and CD2 on the T-cell. For the process of T-cell activation
to continue, the T-cell requires an activation signal from the APC. This “second signal” can be provided by cell surface molecules such as CD80
or CD86, which bind to CD28 on the T-cell. Signal 2 is referred to as “co-stimulation” and is taken to mean an accessory signal(s) that, along with
signal 1, induces “immunity.” This is often measured as T-cell clonal expansion, differentiation into effector cells, and a long-term increase in
precursor frequency (“memory”). Alternatively, CTLA-4 can competitively bind CD80 or CD86, which results in a dampening of the T-cell
response. The requirement for two signals to activate a T-cell is a mechanism for preventing nonspeciﬁc or self-speciﬁc T-cell inﬂammatory
reactions; in the absence of both signal 1 and signal 2, TCR ligation results in anergy rather than activation. APCs therefore have the important
function of determining when an activating second signal should be initiated. They do so by displaying pattern recognition receptors, which
recognize highly conserved molecules expressed by infectious organisms called pathogen-associated molecular patterns. The interaction between
an APC pattern recognition receptor and the pathogen-associated molecular pattern of a microorganism causes the APC to upregulate MHC and
co-stimulatory molecule expression (i.e., CD80 and CD86). Recent observations indicate that APCs also determine the class of immune response
by providing naïve T-cells in the draining lymphoid tissues with signals (signal 3), regulating the development of TH1, TH2, or Tr effector T-cells
or cytotoxic T lymphocytes (CTL). The best-studied TH1-driving factor is IL-12, which binds the IL-12 receptor. Engagement of the IL-12 receptor
co-stimulates Th cell proliferation while selectively upregulating and priming for high IFN- production. IL-12 is an example of a mediator that
delivers a signal 3 that can promote Th1-cell or CTL development.
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standing insulin-dependent diabetes. Thus, it is possible
that daily administration of exogenous insulin could initi-
ate and sustain a systemic anti-insulin T-cell response.
There is a need to have access to pancreatic and lymphoid
tissue from cadaveric donors with signs of autoimmunity
before disease onset to uncover the role for T-cell re-
sponses against islet autoantigens in disease pathogenesis.
By using MHC class II tetramers to probe the TCR
speciﬁcity and avidity of GAD65-reactive T-cell clones
isolated from patients with type 1 diabetes, Reijonen et al.
(22) identiﬁed high-avidity CD4
 T-cells from patients’
peripheral blood. The presence of autoreactive T-cells
with potential preferential usage of TCR to diabetes-
related autoantigens may serve as both a potential marker
for disease progression and a target for immune manipu-
lation in autoimmune diabetes.
Class I–restricted T-cells may also play a critical role in
the development of autoimmune diabetes, as suggested by
the observation that, in newly diagnosed diabetic patients,
islet-inﬁltrating CD8
 T-cells represent the prevalent cell
type of insulitis. The autoantigens targeted by autoreactive
CD8
 T-cells in NOD mice appear to be insulin (23) and
the islet-speciﬁc glucose-6-phosphatase catalytic subunit–
related protein (IGRIP) (24).
Another intriguing observation provided evidence that
peptide 10–18 of the insulin B-chain is related with recur-
rence of autoimmunity and loss of -cell function in
islet-grafted type 1 diabetes recipients (25). Other investi-
gations indicated that islet destruction is caused by auto-
reactive T-cells, whereas the tolerant nondiabetic state is
characterized by autoreactive T-cells that secrete the
immune suppressive cytokine, IL-10 (26).
How much of type 1 diabetes pathoetiology is genetic
and how much is environmental? Perhaps the most
convincing advancement in our knowledge of the genetics
of type 1 diabetes derives from the discoveries of an
autosomal recessive mutation on chromosome 21 causing
the autoimmune polyendocrine syndrome type 1 (APS-I)
(27) and an X chromosome mutation leading to an X-
linked autoimmunity-allergic dysregulation syndrome
(XLAAD; also termed IPEX) (28). The autoimmune poly-
endocrine syndrome type 1 is a rare syndrome with a
relatively high incidence in Finland and Sardinia and
among Iranian Jews, and it is characterized by type 1
diabetes, mucocutaneous candidiasis, hypoparathyroid-
ism, Addison’s disease, and hepatitis. This disease is
caused by a mutation of the autoimmune regulator (AIRE)
gene, which encodes a transcription factor. The gene
product of AIRE is expressed in the thymus, and it might
play an important role in maintaining self-tolerance to
peripheral antigens such as insulin and other tissue-
speciﬁc self-antigens in normal individuals (29). Loss-of-
function mutations in the AIRE gene in autoimmune
polyendocrine syndrome type 1 patients and, for the most
part, in mutant mice lead to progressive autoimmune
destruction of many tissues, including the pancreatic
islets, adrenal cortex, parathyroid glands, and gonads.
The syndrome XLAAD is associated with severe neona-
tal autoimmunity, which is characterized by mononuclear
inﬁltration of multiple organs including pancreatic -cells.
The causative gene, FOXP3 (Foxp3 in mice), and its
protein product that encodes a transcription repressor are
speciﬁcally expressed in CD25
CD4
 T-cells in the thy-
mus and in the periphery. Lack of such regulatory T-cells
lead to overwhelming autoimmunity in humans and mice.
This is an important syndrome to diagnose because bone
marrow transplantation is an effective therapeutic ap-
proach restoring regulatory T-cells in these patients and,
possibly, preventing type 1 diabetes.
The mechanisms by which class II genes inﬂuence
susceptibility to or protection from type 1 diabetes have
been a subject of endless discussions. The crystal struc-
ture of DQ8 and I-A
g7 revealed important similarities
between these two MHC class II molecules, and this
implies that antigen presentation may occur in a compa-
rable fashion in both humans and NOD mice. As a matter
of fact, both DQ8 and IA-g7 bind similar sets of peptides,
including those representing immunodominant epitopes in
NOD mice. Interestingly, in a transgenic NOD mouse
model, the expression of an I-A (the equivalent to the
human class II DQB allele) transgene carrying Asp 57
instead of Ser 57 prevents these mice from developing
diabetes (30).
Brown et al. (31) characterized the structure of the
crystallized HLA class II molecule. One hypothesis is that
effective antigen binding depends on the conformation of
the antigen binding site on the DQ dimer. It has been
postulated that a substitution of an amino acid residue at
these positions of the DQ molecule leads to conforma-
tional changes of the antigen-binding site and, conse-
quently, to a modiﬁcation of the afﬁnity of the class II
molecule for the “diabetogenic” peptide(s). As support for
this hypothesis, it is known that Asp-57 is involved in
hydrogen and salt bonding with both the peptide main
chain and the DR Arg-76 side chain. There are several
highly diabetogenic class II DQ molecules with aspartic
acid at position 57, and thus it is the complete amino acid
sequence rather that any single amino acid residue that is
relevant (32).
Autoimmunity is thought to result from an imbalance
between the two functionally opposite processes, namely
tolerance induction and immune responsiveness, each of
which is dependent on the presence of MHC class I and
class II molecules with appropriate structures (dictated by
the genes encoding them) that are able to present anti-
genic peptides. In genetically susceptible individuals, cer-
tain class II molecules may poorly present self-peptides
because of inefﬁciencies in the peptide-MHC structural
interaction of these molecules, thereby leading to inade-
quate negative selection of T-cell populations that could
later become activated to elicit an islet-speciﬁc destructive
autoimmune response. Nepom and Kwok (33) explained
the molecular basis of HLA-DQ associations with type 1
diabetes exactly on this basis. Paradoxically, some self-
peptides that normally negatively select T-cells are likely
to lead to positive selection when the MHC molecule is, for
example, the HLA-DQ3.2. There are many non-MHC genes
associated with type 1 diabetes, including polymorphisms
inﬂuencing thymic insulin expression and T-cell receptor
signaling (34), with essentially all related to immune
function.
Environmental factors such as congenital rubella and
enteroviruses (particularly Coxsackie B virus) have been
related to type 1 diabetes pathogenesis. The presence of a
viral infection can lead to immune cell activation through
numerous mechanisms. Viruses may directly alter a host
cell that may be lysed, releasing self-peptides and frag-
ments of the host cell into the extracellular milieu,
whereby they may be processed and presented via APCs.
Upon reacting to a viral infection, the immune system may
process and present a homologous viral protein in such a
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can interact with both self-antigens and viral proteins. This
process is termed “molecular mimicry.” GAD, a well-
deﬁned autoantigen in type 1 diabetes, shares similarities
with the P2-C viral sequence of the Coxsackie B virus and
the major outer capsid protein of Rotavirus (35,36). Viral
infections or immunostimulators such as poly I:C, which is
used to stimulate viral infections, can trigger islet autoim-
munity by activating the innate immune system alone, as
demonstrated in the Kilham Rat virus–induced autoim-
mune diabetes model (37).
Recent observations suggest that, in the Aire-deﬁcient
mice model, which causes a number of autoimmune
diseases including autoimmune diabetes, the stochastic
genesis of pathogenic T-cells can initiate autoimmune
disease without the need for environmental stimulation,
underlining the importance of Aire-dependent thymic
deletion rather than an environmental triggering event
(38).
Overall studies on viral elements in the pathogenesis of
type 1 diabetes have been conﬂicting and have failed to
prove conclusively that any of the environmental factors
has an undisputable role in the development of type 1
diabetes in genetically and nongenetically susceptible
individuals. To date, clear conclusions are limited be-
cause most of the studies were not adequately powered
to detect differences in exposure and disease associa-
tions, had inaccurate exposure estimates, and had con-
founding exposures.
WHAT IS THE ANTIGEN?
A common peculiarity of many autoimmune diseases, such
as type 1 diabetes, is the presence of humoral as well as
T-cellular responses directed against multiple autoanti-
gens. Since the early 1980s, many molecular targets of type
1 diabetes–related autoimmune responses have been iden-
tiﬁed, and these include insulin (39), GAD, islet cell
antibody (ICA)512/IA-2 (40), I-A2 (phogrin), and, re-
cently, the zinc transporter Znt8 (Slc30A8) (41). The
majority of studies have largely focused on insulin and
GAD65. Insulin-speciﬁc CD4
 and CD8
 T-cells have
been isolated from islets from young NOD mice and the
insulin peptide (B-chain, amino acid residues 9–23),
which is immunodominant in NOD mice and is also
recognized by human CD4
 and CD8
 cells from pre-
diabetics (20,25).
As autoimmunity in type 1 diabetes progresses from
initial activation to a chronic state, there is often an
increase in the number of islet autoantigens targeted by
T-cells and autoantibodies (42,43). This condition is
termed “epitope spreading.” There is convincing evidence
that islet autoantibody responses against multiple islet
autoantigens are associated with progression to overt
disease (42). More recently, we provided evidence suggest-
ing that a subset of cytoplasmic ICA is related to a more
rapid progression to insulin-requiring diabetes in GAD65
and IA-2 antibody–positive relatives compared with rela-
tives with GAD65 and IA-2 antibodies without ICA (44).
We believe that this ICA response is more than likely
caused by a subset of the ICA reacting with unidentiﬁed
islet autoantigen(s).
Recent studies have suggested a sequential hierarchy in
reactivity to these islet autoantigens (45). Although the
occurrence of immune responses against multiple autoan-
tigens is proportionally associated with the risk of type 1
diabetes progression, the elimination of autoimmune re-
sponses to insulin prevents the development of the disease
in NOD mice. In contrast, transgenic overexpression of
islet-speciﬁc glucose-6-phosphatase catalytic subunit–re-
lated protein (IGRP) resulted in loss of intra-islet IGRP-
speciﬁc T-cells but did not protect NOD mice from insulitis
or type 1 diabetes. These data provide evidence that the
response against IGRP is downstream of the response to
proinsulin (45).
In summary, it is reasonable to hypothesize that the
process of antigenic and epitope spreading is applicable to
autoreactive T-cell responses, which can kill -cells and in
turn lead to release of additional antigens, which can then
be presented to the immune system and give rise to new
T-cell responses reactive to these antigens and further
spreading to new epitopes and antigens.
T-cell antigen receptor. The TCR for MHC-restricted
CD4
 helper and CD8
 cytolytic lymphocytes is a mem-
brane-anchored heterodimeric glycoprotein comprised of
an -chain covalently linked to a -chain. TCR- and -
genes are assembled by somatic DNA recombination dur-
ing T-cell development in the thymus. Many different -
and -chains are expressed within a single individual, and
each T-cell expresses just two -chains and two -chains.
The extracellular part of both the - and -chains consists
of a variable (V) and a constant (C) domain.
T-cell activation requires a sustained interaction be-
tween a naïve T-cell, TCR, and the MCH-peptide complex
on an APC. Exogenous antigens are taken into the APC,
cleaved into peptides, and coupled with MHC molecules
for presentation and recognition by naïve T-cells. T-cells
bear on their surface unique receptors created by genetic
recombinatorial processes. T-cell - and -chains (or 
and ) can be rearranged and paired to produce an
estimated 10
7-10
8 different TCRs in humans.
T-cells from “humanized” TCR transgenic mice are
functional. At least 200 therapeutic strategies can prevent
diabetes in the NOD mice, and some of them might
eventually work in humans. Thus, there is a necessity to
develop a more “robust” murine model that mimics the
opponent difﬁculty of altering the human disease. The
NOD mouse represents a relevant animal model of auto-
immunity in type 1 diabetes. Immunologists analyzed the
effect of genes on immunity using this model of spontane-
ous diabetes, and they generated numerous transgenic
mice on the NOD background to address speciﬁc immu-
nologic questions. Although these models provided impor-
tant clues in understanding autoimmunity in diabetes, they
have signiﬁcant limitations such as numerous differences
in the structure of the immune system between mouse and
humans, which likely result in discrepancies in how the
immune system responds to physiologic and pathologic
stimuli. For instance, the mouse MHC is distinct in many
aspects from that of humans in that the MHC class II is
expressed on activated human but not murine CD4

T-cells. Moreover, human and mouse dendritic cell subsets
express different cell surface markers and receptors, in-
cluding different Toll-like receptors (46). Predisposing
HLA alleles have been introduced and crossed onto mul-
tiple mouse strains that were engineered to develop auto-
immunity. This approach was used to generate transgenic
mice, which would express human components: HLA-DR2
(DRB*0101/DRB1*1501) (Fig. 3), CD4 co-receptor, and a
TCR from a patient-derived T-cell clone recognizing the
dominant myelin basic protein epitope (47). The resulting
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multiple sclerosis.
Recently, Vignali and colleagues (48) developed a novel
approach for the rapid generation of TCR “retrogenic”
mice and established TCR transgenic mice (among them
NOD mice) to be used in studies of autoimmune diabetes
pathogenesis (Fig. 4). Vignali and colleagues generated
mice possessing a monoclonal population of T-cells ex-
pressing 1 of 17 TCRs speciﬁc for known autoantigens
(GAD65, IA2, IA2/phogrin, or insulin), unknown islet
antigens, or control antigens on a NODscid background
using retroviral-mediated stem cell gene transfer and 2A
linked multicistronic retroviral vectors. This TCR retro-
genic approach provides a mechanism by which T-cells
with broad phenotypic differences can be directly com-
pared. Importantly, recent data generated by this ap-
proach suggest that relatively few autoantigen-speciﬁc
TCRs can mediate islet inﬁltration and -cell destruc-
tion. These data strongly advocate that T-cell autoreac-
tivity is not synonymous with pathogenicity (D. Vignali,
personal communication).
A remarkable effect of the MHC complex in type 1
diabetes susceptibility is conferred by the highest-risk
class II genotype (DR3-DQ2:DR4-DQ8) making up one-
third of individuals who develop the disease versus a
population frequency of 2.4% in Denver, Colorado (17). In
addition, HLA molecules such as DQB1*0602 provide
dominant protection from type 1 diabetes in multiple
populations (16).
The general consensus is that the speciﬁcity for -cell
destruction lies in the failure of the host to eradicate or
silence pathogenic T-cells with corresponding TCRs that
recognize epitopes from -cell–derived antigens. In the
NOD mouse model, we have direct data regarding conser-
vation of only the V and J gene segments of T-cell
clones that react with the B:9–23 insulin peptide (49,50).
Mutating this peptide prevents all diabetes (20). Simply
putting back into these double insulin gene knockout mice
a transgene with the normal insulin B:9–23 sequence (in
contrast to transgene with B:9–23 sequence mutated at
position B16) restores development of insulin autoanti-
bodies and insulitis (follow-up to evaluate development of
diabetes is under way). The T-cell -receptor is relatively
simple, with conservation of only two elements (V and
J) and lacking conservation of the -chain N region and
all of the -chain. Zekzer et al. (51) described a CD4

T-cell clone (2H6) derived from pancreatic lymph nodes of
NOD mice that 1) recognized the insulin B:9–23 and
B:12–25 epitopes, 2) produced both transforming growth
factor- and IFN-, 3) were able to home to islets, and 4)
prevented spontaneous diabetes in NOD mice. Remark-
ably, the TCR of this CD4
 T-cell clone shared a common
J chain motif found in three of 50 germ-line J sequences
(Table 1, Fig. 5) but used by the majority of pathogenic
clones reacting with insulin peptide B:9–23.
CENTRAL AND PERIPHERAL TOLERANCE
The concept of breaking of tolerance is fundamental to the
development of autoimmunity. The ﬁrst and perhaps most
vital stage of tolerance induction to self-antigens occurs in
the thymus during T-cell development. Because proteins
with tissue-restricted or peripheral expression are tradi-
tionally thought to be unavailable for presentation in the
thymus, it has been proposed that tolerance to such
proteins can only be achieved through mechanisms of
peripheral tolerance. Indeed, one attractive hypothesis is
that type 1 diabetes is essentially due to failure of negative
selection of autoreactive T-cells, either in the thymus or in
the periphery, or because of a breakdown in tolerance to
T cell
  
Human: TCR/MHC
class II
peptide interaction
APC
TCR
β2
α1 β1
Vβ Vα
Cα Cβ
Mouse
Human
α2
CD4
Peptide
MHC II
FIG. 3. Exempliﬁcation of a human-mouse TCR-MHC class II transgenic mouse model [i.e., HLA-DR2 (DRB1*1501)]. Illustration of a human TCR
class II complex in a TCR transgenic mouse.
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port after thymic transplantation of islet antigens or ex-
pression of putative islet cell autoantigens resulting in
prevention of diabetes in both NOD mouse and BB rat
models (52,53).
There is evidence suggesting that molecules with
tissue-restricted expression are also being expressed in
the thymus (54). Genes encoding the type 1 diabetes–
related autoantigens insulin, IA-2, and GAD and the
neuroendocrine antigen ICA69 are transcribed in human
thymus throughout fetal life and childhood. Insulin gene
transcription in human thymus was also reported by
others, and similarly, insulin, glucagon, GAD, and ICA69
transcripts were detected in mouse and rat thymus
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FIG. 4. “Retrogenic” is a term used for TCR transgenic mice generated by a retrovirus-mediated stem-cell gene transduction of hematopoietic
stem cells with a vector carrying linked TCR - and -chains. The TCR - and -chains are expressed from a single “2A” peptide-linked
multicistronic retroviral vector. The short 2A peptide inserted between the - and -chains encodes a sequence that impairs the formation of a
normal glycine-proline peptide bond at the end of the sequence. This occurs via a “ribosomal skip” mechanism without affecting translation of
the second protein. Naturally occurring 2A sequences are found in many viruses and some parasites. Mouse hematopoietic stem cells transduced
with 2A retroviral vectors are then injected into conditioned mice to reconstitute the mouse with T-cells expressing the transgenic TCR.
TABLE 1
Anti-insulin B:9–23 TCR -chain conservation
Clone Designation V NJ 
Yale clone
2H6 TRAV6S-1 TRAJ53*01 VYHCILR VD SGGSNYKLTFGKGTLLTVTP
BDC (Barbara Davis Center) clones
12-4.1 TRAV5D-4*04 TRAJ53*01 MYFCAAS G A N SGGSNYKLTFGKGTLLTVTP
12-4.4 TRAV5D-4*04 TRAJ53*01 MYFCAAS A SGGSNYKLTFGKGTLLTVTP
6-10.14 TRAV5D-4*04 TRAJ53*01 MYFCAAS S R GGSNYKLTFGKGTLLTVTP
4-7.2 TRAV5D-4*04 TRAJ53*01 MYFCAAS A N GGSNYKLTFGKGTLLTVTP
6-4.3 TRAV5D-4*04 TRAJ53*01 MYFCAAS A S G SGGSNYKLTFGKGTLLTVTP
8-1.3(LN) TRAV5D-4*04 TRAJ42 MYFCAAS A R G SGGSNYKLTFGKGTKLSVKS
12-3.20 TRAV5D-4*04 TRAJ42 MYFCAAS K I GGSNYKLTFGKGTKLSVKS
8-1.9(LN) TRAV5D-4*04 TRAJ42 MYFCAAS R P GGSNYKLTFGKGTKLSVKS
8-1.1(LN) TRAV5D-4*04 TRAJ56 MYFCAAS K TGGNNKLTFGQGTVLSVIP
8-1.5(LN) TRAV5D-4*04 TRAJ13 MYFCAAS A NSGTYQRFGTGTKLQVVP
12-1.19 TRAV13 TRAJ11 TYLCAME R S SGYNKLTFGKGTVLLVSP
12-2.35 TRAV12 TRAJ23 LYFCAAI Q NYNOGKL I FGQGTKLSIKP
6-6.4 TRAV7 TRAJ57 LYYCAPN Q GGSAKL I FGEGTKLTVSS
2/88 V  MYFCAAS 3/50 JKLTFG
Reprinted with permission from the Journal of Clinical Investigation (49). The -chain used to generate the mice described by Homann and
Eisenbarth (49) uses the dominant conserved J chain (TRAJ53*01). Gene segments are in italics. Gene segments that are conserved across
multiple -chains are in italics and boldface. Speciﬁc sequences that are shared across -chains are in boldface but not italics, as they are
not genes.
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thymus, the process of selection would be “blind” to
such self-reactive T-cell clones, which could therefore
escape negative selection. More recent work has iden-
tiﬁed AIRE as the gene responsible for this ectopic
expression of many self-antigens in the thymus, which
causes autoimmune polyendocrinopathy-candidasis-
ectodermal dystrophy (27,57). This rare syndrome is an
example demonstrating that a mutation of a single gene
can give rise to an array of autoimmune polyendocrine
disorders, including autoimmune insulin-requiring dia-
betes. These observations underline the importance of
central tolerance in controlling the generation of auto-
immunity.
Peripheral tolerance occurs in secondary lymphoid or-
gans (i.e., lymph nodes and spleen) and regulates the
activation of naïve T-cells via two mechanisms: anergy and
regulatory T-cells. Anergy involves the clonal inactivation
of T-cells with the potential to respond to self-antigens,
resulting in cells that are resistant to activation upon
antigen encounter. The initial step is selection of T-cells
in the thymus followed by migration to the periphery,
where T-cells encounter the antigen in pancreatic lymph
nodes (58). If primed correctly, activated T-cells trafﬁc
to pancreatic islets, giving rise to a variety of inﬂamma-
tory lesions from mild insulitis to a rapidly destroying
immune-mediated -cell response, leading to fulminant
diabetes.
PROINFLAMMATORY CYTOKINES AND CHEMOKINES:
KILLING OF -CELLS
Multiple mechanisms have been invoked to elucidate how
insulin-producing cells are destroyed. T-cells can directly
kill -cells through a cytotoxic process, but they can also
inﬂuence -cell destruction through multiple factors, in-
cluding the release of proinﬂammatory cytokines, gran-
zyme B, or perforin and, possibly, signaling through
pathways of programmed cell death (59–61). Several
observations suggest that proinﬂammatory cytokines,
such as IL-1, IFN-, and free radicals, are mediators of
pancreatic -cell death (62). There is compelling evidence
that cytokines inﬂuence the expression of inducible nitric
oxide (NO) synthase (iNOS), leading to NO production. In
particular, IL-1IFN-, via NO synthesis, markedly
decreased SERCA2b protein expression, depleted Ca
2
stores, and activated the ER stress pathway, which is a
potential contributing mechanism to -cell death (59).
Furthermore, cytokine-induced (IL-1IFN-) apoptosis
of INS-1 cells seems to be dependent on NO production, as
demonstrated by the use of the NO blocker N
G-methyl-L-
arginine (63). NO contributes to cytokine-induced apopto-
sis through potentiation of Jun NH2-terminal kinase (JNK)
activity and suppression of members of the serine/threo-
nine-speciﬁc protein kinase (Akt) family (63). Although
the role of oxidative stress in the pathogenesis of type 1
diabetes (64) is still a subject of debate, a reduced
TCR   β   chain
MHCII   α   chain
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TRAV5D-04+TRAJ53 Restriction?
Insulin B:9-23: SHLVEALYLVCGERG?
Natural T Regulatory Cells Antigen Specific T Reg
IPEX Syndrome MAN: 
foxP3 mutant DM in days of birth!
NOD anti-B9-23insulin TCR:
foxP3 mutant DM
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g7
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Homann 2006,JCI
TCR   β   chain
MHCII   α   chain
TCR  α  chain
MHCII  β  chain
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FIG. 5. Hypothesis for type 1 diabetes (DM) for humans and the NOD mouse emphasizing recognition of critical islet autoantigenic peptide
presented in groove of class II major histocompatibility antigen (e.g., DR or DQ). For the NOD mouse, insulin is a primary target autoantigen and,
in particular, a peptide of insulin (insulin B:9–23 peptide SHLVEALY) targeted by a conserved T-cell receptor -chain (TRAV5D-04 TRAJ53). The
peptide is presented by a speciﬁc HLA-like molecule (I-Ag7). With loss or abnormalities of antigen-speciﬁc regulatory T-cell function,
development of diabetes is enhanced both for NOD mice and humans (i.e., in the IPEX syndrome, mutation of FOXP3 leads to neonatal
autoimmune diabetes, at times presenting within days of birth).
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diabetic patients compared with healthy control subjects.
Accumulating evidence suggests that pancreatic -cells
are highly susceptible to a situation of protein folding
imbalance termed endoplasmic reticulum (ER) stress (65).
In other words, unfolded proteins accumulate in the ER as
a result of ER stress, triggering apoptosis if this imbal-
anced condition is not reversed. Cytokines IL-1 and
IFN- induce severe ER stress through, respectively, NO-
mediated depletion of ER calcium and inhibition of ER
chaperones, inhibiting -cell defense and augmenting pro-
apoptotic pathways (59). In pancreatic -cells, compo-
nents of an adaptive pathway termed the unfolded protein
response can act as beneﬁcial regulators under physiolog-
ical conditions or promote -cell dysfunction and apopto-
sis under situations of chronic stress. The adaptive
unfolded protein response pathway naturally reduces ER
stress, raising the question of whether enhancing the
unfolded protein response pathway could protect -cells
from death in type 1 diabetes (60). It would be of impor-
tance to further explore the relationship between ER
stress and -cell attrition during autoimmune diabetes
directly in living animals.
Chemokines are chemotactic cytokines that attract leu-
kocytes to tissues. They are subdivided into four families
termed CXC (CXCL 1–16), CX3C (CX3CL1), C (XCL1–2),
and CC (CCL1–28) based on the position of the NH2-
terminal cysteine residues (66). As many as half of known
chemokines have been implicated in the pathogenesis of
type 1 diabetes. Early studies found that pancreas-inﬁltrat-
ing CD4
 T-cells produce a wide range of chemokines
including CCL2, CCL3, CCL4, CCL5, CCL7, CCL12,
CXCL10, and XCL1 (67). More recently, a number of
studies have implicated the CXCR3-binding chemokine,
CXCL10, in the pathogenesis of type 1 diabetes (66). Just
before or at the onset of diabetes, serum CXCL10 levels
seem to be elevated in both human and animal models,
suggesting an accumulation of Th1 lymphocytes. The wide
range of ﬁndings regarding the role of chemokines in the
pathogenesis of type 1 diabetes emphasizes the complex
nature of disease development, and the integration of
these ﬁndings into a coherent perspective on pathogenesis
has been hampered by the fact that the majority of
published expression analyses are limited to quantitation
of chemokine transcripts without corresponding data on
chemokines protein expression as well as mechanistic in
vivo studies.
INNATE IMMUNITY AND TYPE 1 DIABETES
The ﬁrst line of defense against pathogens is obtained
through the response of the innate immune system (68).
Unlike the adaptive immune system, the innate immune
system recognizes pathogens and foreign molecules with-
out having been previously exposed to them and without
generating long-term immunological memory. The innate
immune system achieves this by the use of invariant
pattern recognition molecules, which recognize conserved
molecular patterns present in foreign particles that enter
the host, as well as several cell products that can be
associated with a breach in defenses. These pattern rec-
ognition molecules can be soluble (e.g., collectins, pen-
traxins), membrane-bound (e.g., Toll-like receptors), or
cytosolic (e.g., NOD-like receptors). It has been shown
how deregulation of NOD-like receptors can lead to sev-
eral inﬂammatory conditions, such as inﬂammatory bowel
disease (69) and, possibly, type 1 diabetes.
This innate system uses multiple cell types, including
macrophages, dendritic cells, NK cells, neutrophils, and
epithelial cells, each of which has their own speciﬁc
function in an innate response, from phagocytosis of
infectious pathogens to direct targeted lysis of infected
host cells. Natural killer (NK) cells are involved in killing
target cells, and they interact with APCs and T-cells. It has
been reported that, in longstanding type 1 diabetes, there
is a reduced activation of NK cells (70). It is not clear if this
anomaly is a consequence rather than a cause of disease,
since prolonged hyperglycemia could also explain this
phenomenon. Candidate targets for NK cell recognition in
the pancreatic -cells are ligands for the NKG2D receptor
expressed by NK cells and CD8
 T-cells. A number of
observations suggest that NKG2D plays a role in the
development of autoimmune diabetes in NOD mice (71),
raising the concept that blocking NKG2D interactions with
its ligands or blocking NKG2D signaling could be potential
therapeutic alternatives for type 1 diabetes by preventing
the expansion and function of CD8 T-cells.
Recent observations suggest that innate immunity might
play a role in the development of islet autoimmunity in a
virus-induced murine model of autoimmune diabetes (37).
It has been postulated that TLRs also have the potential to
recognize self-antigens and trigger systemic autoimmune
disease such as systemic lupus erythematosus, rheuma-
toid arthritis, and autoimmune myocarditis (72).
In summary, additional studies are necessary to unravel
the role of innate immunity in type 1 diabetes. Cellular
immunology might provide clues that are indispensable for
further progress. The necessary studies include research
on putative abnormalities within the TLR and NOD-like
receptor pathways, which could be present many years
before the clinical onset of type 1 diabetes.
CONCLUSION
Autoimmunity in general and type 1 diabetes in particular
are the end result of altered pathogenicity and regulation.
In physiologic conditions, there is balance between patho-
genic T-cells that mediate disease such as effector T-cells
with marked conservation of their TCRs (i.e., insulin) and
regulatory T-cells that control autoimmunity. In type 1
diabetes and other autoimmune disorders, there is an
altered balance between pathogenic and regulatory T-
cells. In the next decade, research should target two
speciﬁc pathways: 1) blocking the ability to generate a
pathogenic T-cell response to antigen(s) thought to initiate
the disease and 2) developing genetically engineered Treg-
based cellular therapeutics to suppress pathogenic auto-
immune responses.
In parallel with the experimental work, mathematical
modeling has played a substantial role in the understand-
ing of various disease pathways related to cancer immu-
nology (73). Thus far, the appliance of modeling in
diabetes research has focused mostly on the kinetics of
glucose-induced insulin secretion (74), and only recently
has mechanistic modeling begun to explore speciﬁc path-
ways related to disease, such as the effect of T-cells in
-cell destruction. Several groups are applying multiple
complex system modeling and biosimulation to type 1
diabetes research (Entelos, Archimedes), and our group
believes that there are central elements of this complex
interplay between pathogenic, regulatory T-cells and -cell
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this end, in silico research will likely be complementary to
current experimental approaches in type 1 diabetes re-
search and has the potential to enhance our understanding
of the disease process and assist researchers in designing
laboratory experimentation and in building a framework
for the data collection in an effort to solve biological
uncertainty.
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